Updated Results of the Phase II S1106 Trial of R-hyper-CVAD versus Bendamustine/ Rituximab Followed by ASCT in MCL


Updated Results of the Phase II S1106 Trial of R-hyper-CVAD versus Bendamustine/ Rituximab Followed by ASCT in MCL
Slides from a presentation at ASH 2015 and transcribed comments from a recent interview with Michelle A Fanale, MD (2/18/16)
Chen R et al. Pre-transplant R-bendamustine induces high rates of minimal residual disease in MCL patients: Updated results of S1106: US Intergroup study of a randomized phase II trial of R-HCVAD Vs R-bendamustine followed by autologous stem cell transplants for patients with mantle cell lymphoma. Proc ASH 2015;Abstract 518.

Dr Fanale is Associate Professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center in Houston, Texas.